UPCC 10219: Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer
Enrolling By Invitation
99 years or below
All
Phase
2
32 participants needed
1 Location
Brief description of study
The research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of pancreatic cancer tumors. Subjects will receive Gemcitabine, Abraxane, and PEGPH20.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: pancreatic cancer
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 833642
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
